Crescent Biopharma, Inc. (CBIO) Stock Ticker
CBIO right now
Market factors today
Unlock the full CBIO picture
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
CBIO stock facts
| Ticker symbol | CBIO |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $519.6M |
| CEO | Joshua T. Brumm |
| Employees | 44 |
| Headquarters | Waltham, MA, US |
| IPO date | 2014-01-10 |
| Website | crescentbiopharma.com |
What you can see for CBIO on Tickr
Live CBIO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CBIO report.
Rankings
FAQ
What is the ticker symbol for Crescent Biopharma, Inc.?
The ticker symbol for Crescent Biopharma, Inc. is CBIO, listed on the NASDAQ Capital Market.
What is CBIO?
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a…